Clinical Trials Logo

High Risk of Recurrence clinical trials

View clinical trials related to High Risk of Recurrence.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02260505 Completed - Clinical trials for Gastrointestinal Stromal Tumors

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

ImadGist
Start date: December 24, 2014
Phase: Phase 3
Study type: Interventional

This is a 2 arms study concerning patients with primary GIST who followed an Imatinib adjuvant treatment for 3 years after surgery and who have a high risk of recurrence. In the first arm, patients will continue Imatinib treatment for 3 more years, allowing to determine if the continuation of this treatment is efficient for disease control, in terms of Disease Free Survival improvement. In the second arm, patients will discontinue the Imatinib treatment, as standard practice. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease.